# CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms

> **NCT04467918** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University of Sao Paulo** · enrollment: 100 (estimated)

## Conditions studied

- SARS-CoV2

## Interventions

- **DRUG:** Cannabidiol
- **OTHER:** PLACEBO

## Key facts

- **NCT ID:** NCT04467918
- **Lead sponsor:** University of Sao Paulo
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-06
- **Primary completion:** 2021-11-16
- **Final completion:** 2021-11-16
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04467918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04467918, "CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04467918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*